Science ❯ Psychopharmacology

Psychedelics

Clinical Trials Therapeutic Effects MDMA Psilocybin LSD Neurobiology DMT

FDA Clears First U.S. Human Trial of Ibogaine Derivative for Alcohol Use Disorder

The FDA move signals a federal shift to speed psychedelic studies under new White House directives.

Single IV DMT Dose With Therapy Shows Rapid, Lasting Antidepressant Effect in Phase IIa Trial

Five-Year Follow-Up Finds 67% Remission After Psilocybin-Assisted Therapy

Single 100-Microgram Dose of LSD Drug Eased GAD for 12 Weeks in JAMA Trial

Single Psilocybin Dose Delivers Two-Year Relief From Depression and Anxiety in Cancer Patients

Psilocybin Therapy Shows Promise for Millions with Depression

FDA Declines MDMA for PTSD Treatment, Requests Further Trials